cannabis rescheduling

President Donald Trump's pick to run the Drug Enforcement Administration (DEA) is apparently considering a proposal to federally reschedule cannabis. The DEA administrator nominee, Terrance Cole, says it will be "one of my first priorities" if he's confirmed. "If confirmed, it'll be one of my first...

President Donald Trump has tapped Terrance Cole, a former 22-year DEA official and Virginia public safety administrator, to take the helm of the Drug Enforcement Administration (DEA). Trump announced the appointment Tuesday afternoon in a social media post. "Together, we will save lives, and MAKE...

A new poll by NuggMD reveals a stark divide between frequent cannabis consumers and the Drug Enforcement Administration (DEA). According to the survey, conducted between January 16 and January 19, 2025, only 4% of respondents trust the DEA to be an “unbiased proponent” for cannabis...

Safe Harbor Financial (NASDAQ:SHFS), which provides secure and compliant financial services for the regulated cannabis industry, announced it had surpassed $25 billion in processed cannabis-related funds through its network of partner banks. This milestone aligns with the company’s 10th...

A federal judge delayed a pivotal hearing on the Biden administration's proposal to ease restrictions on marijuana, citing serious allegations of misconduct within the Drug Enforcement Administration (DEA). On Monday afternoon, Administrative Law Judge John Mulrooney canceled the Jan. 21 hearing,...

Amplify ETFs announced Wednesday that it plans to liquidate the Amplify U.S. Alternative Harvest ETF (NYSE:MJUS), with trading set to end Jan. 27. The Amplify U.S. Alternative Harvest ETF has a significant allocation to cannabis-related companies like Green Thumb Industries (OTC:GTBIF) and Curaleaf...

In a new twist on Wednesday, a DEA judge ordered the agency to respond to allegations that it opposes President Joe Biden's directive of August 2023 to reschedule marijuana and that it is improperly conferring with cannabis opponents. Marijuana Moment reported that one day after a motion was filed...

In 2024, the cannabis landscape in the United States experienced some developments, though federal legalization or removal from the Controlled Substances Act (CSA) did not occur under the Biden administration, though that was promised to voters on a regular basis. “No one should be in jail...

The long-awaited hearing to discuss cannabis rescheduling will begin on January 21, 2025, marking a significant moment in the ongoing debate over cannabis regulation. As Business of Cannabis reported, the six-week hearing will continue until March 6, 2025, but its outcome remains uncertain due to...

Attorney Matt Zorn is suing the Drug Enforcement Administration (DEA) for failing to release records related to its communications with Smart Approaches to Marijuana (SAM), an anti-cannabis group. This lawsuit, filed November 28, seeks to compel the DEA to produce these records under the Freedom of...

The Drug Enforcement Administration (DEA) launched its inaugural hearing on Monday December 2, 2024, to address the Biden administration's proposal to reclassify marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA). According to a DEA advisory released on November 26...

As the formal review process for rescheduling cannabis unfolds, industry players are closely watching its potential to transform the sector. With the DEA hearing delayed until early 2025 and a possible Trump presidency adding uncertainty, cannabis businesses are preparing for what rescheduling to...

The Drug Enforcement Administration (DEA) will hold its first hearing on December 2 to address the Biden administration’s proposal to reclassify marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA). The hearing, announced through a public advisory on November 26...

Smart Approaches to Marijuana (SAM), an active prohibitionist group, has denied allegations of improper communications with the Drug Enforcement Administration (DEA) ahead of next week’s cannabis rescheduling hearing. SAM's Nov. 25 legal response dismissed the claims as unfounded and aimed...

A DEA administrative law judge has denied MedPharm's motion to participate in the December 2 marijuana rescheduling hearing, deferring to DEA Administrator Anne Milgram's authority. MedPharm, a DEA-registered research firm, criticized the exclusion of marijuana researchers and the inclusion of...